GMED heads into its May 5 Q1 2026 earnings report with options traders unusually bullish and the analyst community firmly in the company's corner — a setup that leaves little room for disappointment.
The clearest signal comes from options. Positioning is more bullish than at almost any point in the past year. The put/call ratio has fallen to 0.36, well below its 20-day average of 0.41 and sitting near the lower end of its 52-week range (0.03–0.70). At 1.1 standard deviations below the recent mean, the tilt toward calls indicates that options traders are not hedging — they are leaning into the print. That said, short interest is creeping higher ahead of the report. Shorts in GMED have risen 16% over the past week to 3.1% of the free float. That is still a modest level in absolute terms, and borrow availability remains loose — cost to borrow has eased 24% over the same period to just 0.38% annualised. The lending market is not under stress.
The bull case centres on the pace of spine market recovery and the ongoing integration of NuVasive. Analysts have been steadily lifting targets since late 2025, with Wells Fargo, Barclays, Needham, and Piper Sandler all raising price objectives in the months after the last earnings print in February. The consensus is a clean buy, with a mean target around $111, implying roughly 21% upside to the current price of $91.34. The stock is up 6% over the past month but still off around 4% on the week, suggesting some pre-earnings jitter. Bears focus on the integration risk: the merged NuVasive and Nevro businesses could drag growth to low-single digits while margins stay flat, a scenario that would test a near-20x earnings multiple. At EV/EBITDA of around 10.8x, valuation is not stretched, but it does assume the integration narrative holds.
Institutional holders are largely passive and stable. Invesco added nearly 2.9 million shares in Q1, a notable position build for a fund that previously held far fewer. Founder and largest shareholder David Paul retains 16.5% of the company. Insider activity over the past 90 days has been exclusively selling — the CFO, general counsel, and several independent directors all trimmed positions — though at trade significance scores of just 2, these read more as routine liquidity events than conviction signals.
After the last two confirmed earnings events, the stock gained roughly 2–3% on the day before softening over the following week. The May 5 print will test whether accelerating spine market momentum and cleaner post-merger execution can justify the Street's optimism — or whether integration friction starts to show up in the numbers.
See the live data behind this article on ORTEX.
Open GMED on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
